APR 0 2 2001 E

37 CFR 1.501 INFORMATION DISCLOSURE STATEMENT IN A PATENT

(use several sheets if necessary)

Docket No. 112703-035

Serial No. \\ 09/286.818

Applicant

Ream et al. Filing Date April 6, 1999

Group Art

		1	U.S. PATENT DO	CUMENTS			11000	2	
Examiner's Initials		Document Number	Date	Name	Class	Subclass	Filing I appro	f	
9.T	AA	4,154,814	May 15, 1979	Hand et al.			пррго	priate	
<u> </u>	AB	4,400,372	Aug. 23, 1983	Muhler et al.					
	AC	4,474,749	Oct. 2, 1984	Kruppa					
	AD	4,563,345	Jan. 7, 1986	Arrick			<u> </u>		
	AE	4,647,450	Mar. 3, 1987	Peters et al.	·				
	AF	4,755,389	July 5, 1988	Jones et al.					
	AG	4,822,597	Apr. 18, 1989	Faust et al.					
	AH	4,822,816	Apr. 18, 1989	Markham					
	AI	4,828,820	May 9, 1989	Glass et al.			-		
	AJ	4,832,994	May 23, 1989	Fey					
	AK	4,849,227	July 18, 1989	Cho					
<u> </u>		1 ' '	REIGN PATENT	DOCUMENTS			<u> </u>		
	T		1				Trans	lation	
		Document Number	Date	Country	Class	Subclass	Yes	No	
	AL	84/02271	June 21, 1984	PCT WO					
	AM	90/12583	Nov. 1, 1990	POT WO					
	AN	92/06680	Apr.30, 1992	PCT WO					
	AO	2,706,771	June 21, 1993	France					
	AP	OTHER ART (Incl					4:1_	L	
		Akitoshi et al., Abstract "Acceleration of Transdermal Absorption of Pharmaceuticals by Essential Oils and Organic Solvents," Chem. Abst., 112:125228t, 1990.							
	AQ	Bradford, A Rapid and Sensitive Method for the Quantification of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding, Analytical Biochemistry, 72:248-254 (1976).							
	AR	Nielsen et al., P-Glycoprotein as Multidrug Transporter: A Critical Review of Current Multidrug Resistant Cell Lines, Chimica et Biophysica Acta., 1139:169-183 (1992).							
	AS	Adams, M.W., d-Alpha Tocopheryl Polyethylene glycol 1000 Succinate (Eastman vitamin E TPGS) as an Emulsifier and Bioenhancer for Drugs and Lipophilic Compounds, 6th International Conference on Pharmaceutical Technology, Paris, 2-4 June, 1992.							
S.T Examiner	AT Chang, Tammy et al., "The Effect of Water-Soluble Bitamin E on Cyclosporine Pharmacokinetics in Healthy Volunteers," Abstract in American Society to Clinical Pharmacology and Therapeutics, 57(2):163, Feb. 1995.								
Exammer		9,5	Date Considered	5/29/01					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 4

37 CFR 1.501 INFORMATION DISCLOSURE STATEMENT IN A PATENT

(use several sheets if necessary)

Docket No. Serial No. 112703-035 O97286,818

Applicant Ream et al. Filing Date April 6, 1999 Units

						,	17610	
		U.	S. PATENT DOC	UMENTS			90	
Examiner's							Filing Bate	
nitials		Document Number	Date	Name	Class	Subclass	If appropriat	
3.T	BA	4,853,212	Aug. 1, 1989	Faust et al.				
•	BB	4,867,989	Sep. 19, 1989	Silva et al.				
	BC	4,908,211	Mar. 13, 1990	Paz				
	BD	4,908,212	Mar. 13, 1990	Kwon et al.	†			
	BE	4,929,447	May 29, 1990	Yang				
	BF	4,933,184	June 12, 1990	Tsuk				
	BG	4,938,963	July 3, 1990	Parnell	1			
-	BH	4,944,949	July 31, 1990	Story et al.				
	BI	4,968,716	Nov. 6, 1990	Markham				
	BJ	5,015,464	May 14, 1991	Strobridge				
	BK	5,070,085	Dec. 3, 1991	Markham				
	BM BN	Cytochrome P450IIIA4" (1989) Molec. Pharm. 36:89-96. BN Lalka et al.; "The Hpatic First-Pass Metabolism of Problematic Drugs" (1993) J. Clin Pharmacol. 33:657-669. BO Lum et al.; "Clinical Trials of Modulation of Multidrug Resistance. Pharmacokinetic Pharmacodynamic Considerations" (1993) Cancer 72:3502-3514.						
	BP Muranishi, Shozo; "Absorption Enhancers" (1990) Crit. Rev. Ther. Drug Carrier Sys. 33.							
	BQ	for the 1990's" (1993) J. Clin. Pharmacol. 33:670-673.						
	BR	Tam, Yun K.; "Indiv 25:300-307.			`		*	
	BS	Van Hoogdalem et al.; "Intestinal Drug Absorption Enhancement: An Overview" (1989 <i>Pharmacol. Ther.</i> 44:407-443.						
	BT	Warren et al.; "Incre Liposomes" (1992) (Cancer Research 52	2:3241-3245.				
81	BU	Watkins, Paul B.; "T Am. Acad. Dermaco.	<i>l</i> . 23:1301-1311.			ine Metabo	lism" (1990) <i>J</i>	
xaminer		2 T	Date Considered	5/29/8				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



37 CFR 1.501 INFORMATION DISCLOSURE STATEMENT IN A PATENT

(use several sheets if necessary)

Docket No. 7 112703-035

Serial No. 09/286.818

Applicant Ream et al.

Filing Date Gro April 6, 1999 Uni

Group Art

							1761
		U.S	S. PATENT DOC	UMENTS		,	
Examiner's Initials		Document Number	Date	Name	Class	Subclass	Filing Date If appropriate
SIT	CA	5,124,156	June 23, 1992	Shibata et al.			
	CB	5,139,787	Aug. 18, 1992	Broderick et al.			
	CC	5,154,927	Oct. 13, 1992	Song et al.			
	CD	5,156,842	Oct. 20, 1992	Mulligan	1		
	CE	5,179,122	Jan. 12, 1993	Greene et al.			
	CF	5,182,099	Jan. 26, 1993	Jonsson et al.	1		
	CG	5,284,657	Feb. 8, 1994	Lu et al.			
	CH	5,294,449	Mar. 15, 1994	Greenberg			
	CI	5,340,566	Aug. 23, 1994	Curtis et al.	<u> </u>		
	CJ	5,378,131	Jan. 3, 1995	Greenberg		, .	
	CK	5,380,530	Jan. 10, 1995	Hill			
	CL	5,380,535	Jan. 10, 1995	Geyer et al.			
	CM	5,410,028	Apr. 25, 1995	Asami et al.	 		
	CN	5,445,834	Aug. 29, 1995	Burger et al.			
	CO	5,455,286	Oct. 3, 1995	Amidon et al.			
	CP	5,488,962	Feb. 6, 1996	Perfetti			
	CQ	5,496,541	Mar. 5, 1996	Cutler			
	CR	5,512,306	Apr. 30, 1996	Carlsson et al.			
	CS	5,534,272	July 9, 1996	Bernstein			
	CT	5,554,380	Sept. 10, 1996	Cuca et al.		-	
	CU	5,571,528	Nov. 5, 1996	Lee et al.			
	CV	5,585,110	Dec. 17, 1996	Kalili et al.	<u> </u>		
-	C	THER ART (Includ	ing Author, Title	. Date. Pertinent 1	Pages, E	tc.)	
	CW	Wrighton et al.; "In	Vitro Methods for	Assessing Human	Hepatic	Drug Meta	bolism: The
		Use in Drug Develop					
	CX	Wu et al.; "Use of IV and Oral Drug Levels from Cyclosporene (CsA) with Concomitant Rifampin to Differentiate Gut Absorption and Metabolism" (1993) <i>Pharm. Res.</i> 10:abstract ppdm8185.					
SIT	- CY	Zamora et al.; "Phys Multidrug Resistance	ical-Chemical Pro e in Human Louk	emic Cells" (1988)	Compour Molec.	nds that Mo	dulate 33:454-462.
Examiner		S T I if reference conside	Date Considered				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



37 CFR 1.501 INFORMATION DISCLOSURE STATEMENT IN A PATENT

IN A PATENT (use several sheets if necessary)

Docket No. () 112703-035

| Serial No. [| 09/286,818

Applicant

Ream et al. Filing Date April 6, 1999

Group Art Unit

		U.S	S. PATENT DOC	CUMENTS		·	
Examiner's Initials		Document Number	Date	Name	Class	Subclass	Filing Dat If appropriat
5.5	DA	5,593,685	Jan. 14, 1997	Bye et al.			-11 1
1	DB	5,605,698	Feb. 25, 1997	Ueno -			
	DC	5,618,517	Apr. 8, 1997	Miskewitz			
	DD	5,628,986	May 13, 1997	Sanker et al.			
	DE	5,629,035	May 13, 1997	Miskewitz			·
	DF	5,645,853	July 8, 1997	Winston et al.			
	DG	5,665,386	Sept. 9, 1997	Benet et al.			
	DH	5,667,802	Dec. 16, 1997	Grimberg			
	DI	5,693,334	Dec. 2, 1997	Miskewitz			
	DJ	5,698,215	Dec. 16, 1997	Kalili et al.			
	DK	5,702,687	Dec. 30, 1997	Miskewitz			
	DL	5,716,928	Feb. 10, 1998	Benet et al.			
	DM	5,736,175	Apr. 7, 1998	Cea et al.			
	DN	5,744,164	Apr. 28, 1998	Chauffard et al.			
	DO	5,753,255	May 19, 1998	Chavkin et al.			
	DP	5,756,074	May 26, 1998	Ascione et al.		,	
	DQ	5,824,291	Oct. 20, 1998	Howard			
	DR	5,866,179	Feb. 2, 1999	Testa			
	DS	5,882,702	Mar. 16, 1999	Abdel-Malik et al.			
	DT	5,900,230	May 4, 1999	Cutler			-
	DU	5,912,030	June 15, 1999	Huziinec et al.			
	DV	5,922,346	July 13, 1999	Hersh			
	DW	5,958,380	Sept. 28, 1999	Winston et al.			
T, e	DX	5,958,472	Sept. 28, 1999	Robinson et al.			
Examiner		3 (T	Date Considered	5/20/0	1		······

Examiner S T Date Considered 5/20 (5)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.